Genaera Corporation Implements Cash Conservation Plan
...rder to maintain the ability to pursue business development strategies for trodusquemine (MSI-1436), the first-in-class, highly selective inhibitor of ptp1b
and Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity, and explore strategic alternatives. The Company will also activel...
Genaera to Present at BIO CEO & Investor Conference
...and Chief Executive Officer, will provide promising preliminary Phase 1b clinical data for MSI-1436, the first-in-class, highly selective inhibitor of ptp1b
and Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity, on Tuesday, February 10, 2009 at 2:15 p.m. (ET).
Low Doses of Red Wine Chemical May Fight Diabetes
...of the editorial.
"But it can make animals want less food and lower body weight," she said. "By activating SIRT1, you could block the expression of ptp1b
and get the same hopeful benefit."
But clearly, "further studies are needed by other researchers and on different tissues in animals," Zabolotny sa...
Possible safer target for anti-clotting drugs found
...yrosine phosphatase-1B. When the mice were given a ptp1b
inhibitor, the reduced platelet aggregation was re...red. When calpain-1 knockout mice and mice lacking ptp1b
were crossed to create double-knockout mice, plate.... The researchers were thus able to establish that ptp1b
turns off the signal for platelet aggregation and ...
Blocking Enzyme Can Treat Breast Cancer
...fuels the growth of breast cancer.
The enzyme ptp1b
appears to fuel tumor growth and drugs that block ... McGill University in Montreal found that deleting ptp1b
in mice led to a significant delay in the onset of...nline edition BBC News.
Over-expression of ptp1b
has already been implicated in the development of ...
New Findings In Breast Cancer
...with the spread of breast cancer//.
The gene ptp1b
is known for its role in diabetes and obesity, exp...
"In this new study, we found that the role of ptp1b
in modulating metabolism is equally crucial in the...d that suppressing the enzyme produced by the gene ptp1b
made it possible to cure type II diabetes and obes...
Suppression of Enzyme Delays a Type of Breast Cancer
...ave disclosed that suppression of an enzyme called ptp1b
stalls the advancement of a specific type of breas...lop at all.
On the other hand, when the enzyme ptp1b
was expressed it resulted in the development of ca...d by this enzyme suppression. In addition to this, ptp1b
inhibitors have been developed by drug companies t...
Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
...trodusquemine (MSI-1436), the first-in-class, highly selective inhibitor of ptp1b
and Genaera's lead drug candidate for the treatment of type 2 diabetes and ...commented Mr. Armstrong. "MSI-1436 continues to exhibit promise as the only ptp1b
inhibitor in development to simultaneously treat both type 2 diabetes and o...
Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
...emine is a centrally and peripherally-acting appetite
suppressant and the first highly selective inhibitor of protein tyrosine
phosphatase 1B (PTP1B). ptp1b
is central to controlling the function of
both the leptin and insulin pathways. By inhibiting PTP1B, MSI-1436 is
expected to decrease appetite and nor...
Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
...sented "Trodusquemine: A First-in-Class
Inhibitor for the Treatment of Type 2 Diabetes and...the blood-brain barrier and
functionally inhibited ptp1b
in the hypothalamus. In this study, rats were
admi...-1436 is a reversible, noncompetitive
inhibitor of ptp1b
with the ability to cross the blood brain barrier....
VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
...reast, ovarian, colorectal, pancreatic, and hematologic cancers;
Lenocta(TM), an inhibitor of specific protein tyrosine phosphatases SHP-1,
SHP-2, and ptp1b
that has demonstrated clinical and biological activity in
solid tumors; and Xyfid(TM), a topical therapy which is being developed for
the treatment an...
Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
...436C-101 presented at Genaera's poster session, "First in Human Use of MSI-1436 (Trodusquemine), a Centrally and Peripherally Acting Selective ptp1b
Inhibitor," demonstrated that the drug was safe and well tolerated by the healthy, overweight and obese volunteers at doses well above the ant...